1.
Viral hepatitis B
by Lai, Ching Lung
The Lancet (British edition), 2003-12-20, Vol.362 (9401), p.2089-2094
2.
Review article: novel therapies for hepatitis B virus cure – advances and perspectives
by Lin, C.‐L.
Alimentary pharmacology & therapeutics, 2016-08, Vol.44 (3), p.213-222
3.
A comparison of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive patients: a prospective cohort study in China
by Zhang, Y
Clinical microbiology and infection, 2016-03, Vol.22 (3), p.287.e1-287.e9
4.
Meta-analysis: oral anti-viral agents in adults with decompensated hepatitis B virus cirrhosis
by Singal, A. K.
Alimentary pharmacology & therapeutics, 2012-03, Vol.35 (6), p.674-689
5.
Control of hepatitis B in China: prevention and treatment
by Wang, Yu
Expert review of anti-infective therapy, 2011-01-01, Vol.9 (1), p.21-25
6.
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study
by Marcellin, Patrick, Prof
The Lancet (British edition), 2013, Vol.381 (9865), p.468-475
7.
HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B
by Nassal, Michael
Gut, 2015-12, Vol.64 (12), p.1972-1984
8.
Hepatitis B virus infection
by Liaw, Yun-Fan, Prof
The Lancet (British edition), 2009, Vol.373 (9663), p.582-592
9.
HIV-hepatitis B virus coinfection: epidemiology, pathogenesis, and treatment
by Singh, Kasha P
AIDS (London), 2017-09-24, Vol.31 (15), p.2035-2052
10.
Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis
by Zoutendijk, Roeland
Gut, 2013-05, Vol.62 (5), p.760-765
11.
Chronic hepatitis E in HIV/HBV coinfected patient: lack of power of sofosbuvir–ribavirin
by Todesco, Eve
AIDS (London), 2017-06-01, Vol.31 (9), p.1346-1348
12.
Recommendations for screening, monitoring, prevention, prophylaxis and therapy of hepatitis B virus reactivation in patients with haematologic malignancies and patients who underwe...
by Sarmati, L
Clinical microbiology and infection, 2017-12, Vol.23 (12), p.935-940
13.
HIV, hepatitis B virus, and hepatitis C virus co-infection in patients in the China National Free Antiretroviral Treatment Program, 2010–12: a retrospective observational cohort st...
by Zhang, Fujie, Prof
The Lancet infectious diseases, 2014, Vol.14 (11), p.1065-1072
14.
15.
Genetic basis of hepatitis virus-associated hepatocellular carcinoma: linkage between infection, inflammation, and tumorigenesis
by Takeda, Haruhiko
Journal of Gastroenterology, 2016-10-06, Vol.52 (1), p.26-38
16.
Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial
by Janssen, Harry LA
The Lancet (British edition), 2005, Vol.365 (9454), p.123-129
17.
Evaluation of the immune response to hepatitis B vaccine in patients on biological therapy: results of the RIER cohort study
by Richi, Patricia
Clinical rheumatology, 2020-04-04, Vol.39 (9), p.2751-2756
18.
Towards an HBV cure: state-of-the-art and unresolved questions—report of the ANRS workshop on HBV cure
by Zeisel, Mirjam B
Gut, 2015-08, Vol.64 (8), p.1314-1326
19.
Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009
by Poon, Donald, Dr
The lancet oncology, 2009, Vol.10 (11), p.1111-1118
20.
Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B
by Patterson, S J
Gut, 2011-02, Vol.60 (2), p.247-254
